Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.43 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1907236 | 0.87 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL1905870 | 0.86 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL1907945 | 0.86 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL1906973 | 0.84 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL1908346 | 0.84 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL1907483 | 0.84 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11MEN1 | |
| SCHEMBL1906495 | 0.84 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL5175081 | 0.84 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL1906382 | 0.84 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL1904902 | 0.83 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4684515-B2 | — | — | 2011-05-18 | — | — | JP | claimed |
| US-6541670-B2 | Antiinflammatory agents | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-04-01 | — | — | US | claimed |
| US-20030013770-A1 | Aminobenzophenones as inhibitors of il 1b and tnf | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-01-16 | — | — | US | claimed |
| EP-1237845-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-09-11 | — | — | EP | claimed |
| WO-2001042189-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | LEO PHARMA A/S (DK) | 2001-06-14 | — | — | WO | claimed |
| EP-1237845-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2007-05-23 | — | — | EP | disclosed |
| US-6541670-B2 | Antiinflammatory agents | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-04-01 | — | — | US | disclosed |
| US-20030013770-A1 | Aminobenzophenones as inhibitors of il 1b and tnf | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013770-A1 | Aminobenzophenones as inhibitors of il 1b and tnf | IL1B, IL1A, IL6 | MAPK14 1553/4885MAPK13 2221/4885MAPK12 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.